BioCentury | Dec 31, 2020
Emerging Company Profile

Cardior: targeting microRNAs to treat heart failure

Cardior plans to build on early clinical data for its antisense oligonucleotide in heart failure patients by moving the RNA therapy into niche indications where it believes the product can help dysfunctional...
BioCentury | Dec 4, 2020
Distillery Therapeutics

Scripps team discovers RNA-targeting small molecule for myotonic and corneal dystrophies

DISEASE CATEGORY: Musculoskeletal; ophthalmic disease INDICATION: Myotonic dystrophy type 1 (DM1); ophthalmic A Scripps Research team led by Expansion Therapeutics Inc. co-founder Matthew Disney has designed an RNA-targeting small molecule that could treat DM1 and Fuchs...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...sickling propensity, and metabolic markers such as ATP...
BioCentury | Nov 13, 2020
Product Development

Next-generation sickle cell readouts at ASH: Data Byte

...health, including levels of different types of hemoglobin, sickling propensity, and metabolic markers such as ATP...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Exon skipping therapy for Batten disease

...accumulation of the subunit c of mitochondrial ATP...
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), also continues to have a stake in its success.TARGETSACLY – ATP...
BioCentury | Jul 25, 2020
Product Development

NIH, HHS fast-tracking point-of-care, pooled tech as way out of testing crunch

...the initiative’s RADx-Advanced Technologies Platforms (RADx-ATP) program, which fast-tracks them into Phase 1 or 2. RADx-ATP...
BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

...$21 million. Staff Writer Hongjiang Li contributed to this report. Targets ABCC6 (MRP6; PXE) - ATP-binding...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

...Discovery Institute also uses Vero cells, but quantifies cell killing and rescue by measuring cellular ATP...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

...Venture Investments CEO: Kevin Finney Patents: Four issued patents including composition claims Targets ABCD1 - ATP...
Items per page:
1 - 10 of 747
BioCentury | Dec 31, 2020
Emerging Company Profile

Cardior: targeting microRNAs to treat heart failure

Cardior plans to build on early clinical data for its antisense oligonucleotide in heart failure patients by moving the RNA therapy into niche indications where it believes the product can help dysfunctional...
BioCentury | Dec 4, 2020
Distillery Therapeutics

Scripps team discovers RNA-targeting small molecule for myotonic and corneal dystrophies

DISEASE CATEGORY: Musculoskeletal; ophthalmic disease INDICATION: Myotonic dystrophy type 1 (DM1); ophthalmic A Scripps Research team led by Expansion Therapeutics Inc. co-founder Matthew Disney has designed an RNA-targeting small molecule that could treat DM1 and Fuchs...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...sickling propensity, and metabolic markers such as ATP...
BioCentury | Nov 13, 2020
Product Development

Next-generation sickle cell readouts at ASH: Data Byte

...health, including levels of different types of hemoglobin, sickling propensity, and metabolic markers such as ATP...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Exon skipping therapy for Batten disease

...accumulation of the subunit c of mitochondrial ATP...
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), also continues to have a stake in its success.TARGETSACLY – ATP...
BioCentury | Jul 25, 2020
Product Development

NIH, HHS fast-tracking point-of-care, pooled tech as way out of testing crunch

...the initiative’s RADx-Advanced Technologies Platforms (RADx-ATP) program, which fast-tracks them into Phase 1 or 2. RADx-ATP...
BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

...$21 million. Staff Writer Hongjiang Li contributed to this report. Targets ABCC6 (MRP6; PXE) - ATP-binding...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

...Discovery Institute also uses Vero cells, but quantifies cell killing and rescue by measuring cellular ATP...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

...Venture Investments CEO: Kevin Finney Patents: Four issued patents including composition claims Targets ABCD1 - ATP...
Items per page:
1 - 10 of 747